461 results on '"Wilding, John P. H."'
Search Results
2. SGLT2 Inhibitors – The New Standard of Care for Cardiovascular, Renal and Metabolic Protection in Type 2 Diabetes: A Narrative Review
3. Body Fat Depletion: the Yin Paradigm for Treating Type 2 Diabetes
4. Etiopathogenesis of Obesity
5. Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial
6. Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial
7. #2496 Effect of semaglutide on kidney outcomes in people with overweight or obesity and established cardiovascular disease in the SELECT trial
8. Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial
9. The Place and Value of Sodium-Glucose Cotransporter 2 Inhibitors in the Evolving Treatment Paradigm for Type 2 Diabetes Mellitus: A Narrative Review
10. The double burden of malnutrition in individuals: Identifying key challenges and re‐thinking research focus.
11. Body Fat Depletion: the Yin Paradigm for Treating Type 2 Diabetes
12. Natriuretic Peptides, Body Mass Index and Heart Failure Risk: Pooled Analyses of SAVOR‐TIMI 53, DECLARE‐TIMI 58 and CAMELLIA‐TIMI 61
13. SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications
14. The efficacy and safety of dapagliflozin in women and men with type 2 diabetes mellitus
15. Estimating and reporting treatment effects in clinical trials for weight management: using estimands to interpret effects of intercurrent events and missing data
16. The prevalence of cardiac autonomic neuropathy in prediabetes: a systematic review
17. Obesity and Obstructive Sleep Apnea Syndrome
18. Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study
19. No evidence of compensatory changes in energy balance, despite reductions in body weight and liver fat, during dapagliflozin treatment in type 2 diabetes mellitus: A randomized, double‐blind, placebo‐controlled, cross‐over trial (ENERGIZE)
20. Corneal Confocal Microscopy Predicts Cardiovascular and Cerebrovascular Events and Demonstrates Greater Peripheral Neuropathy in Patients with Type 1 Diabetes and Foot Ulcers
21. Should obesity be recognised as a disease?
22. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial
23. Etiopathogenesis of Obesity
24. Safety of Ipragliflozin in Patients with Type 2 Diabetes Mellitus: Pooled Analysis of Phase II/III/IV Clinical Trials
25. Cardiac Autonomic Neuropathy in Obesity, the Metabolic Syndrome and Prediabetes: A Narrative Review
26. Metabolically healthy obesity: time for a change of heart?
27. Patients’ Perspectives of Oral and Injectable Type 2 Diabetes Medicines, Their Body Weight and Medicine-Taking Behavior in the UK: A Systematic Review and Meta-Ethnography
28. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial
29. 1α,25(OH)2D3 attenuates IL-6 and IL-1β-mediated inflammatory responses in macrophage conditioned medium-stimulated human white preadipocytes by modulating p44/42 MAPK and NF-κB signaling pathways
30. Short-term decreased physical activity with increased sedentary behaviour causes metabolic derangements and altered body composition: effects in individuals with and without a first-degree relative with type 2 diabetes
31. Management of obesity
32. Regulation of energy balance — towards rational drug design in obesity
33. The endocannabinoid system as a target for obesity treatment
34. Intestinal lipase inhibitors
35. Sibutramine
36. Physical Activity and Sedentary Time: Association with Metabolic Health and Liver Fat
37. Efficacy and Safety of Dapagliflozin According to Background Use of Cardiovascular Medications in Patients With Type 2 Diabetes
38. Obesity and cardiovascular disease: mechanistic insights and management strategies. A joint position paper by the World Heart Federation and World Obesity Federation
39. Medication use for the treatment of diabetes in obese individuals
40. Correction to: Cardiac Autonomic Neuropathy in Obesity, Metabolic Syndrome and Prediabetes: A Narrative Review
41. The effects of empagliflozin, dietary energy restriction, or both on appetite‐regulatory gut peptides in individuals with type 2 diabetes and overweight or obesity: The SEESAW randomized, double‐blind, placebo‐controlled trial
42. Neuropsychiatric safety with liraglutide 3.0 mg for weight management: Results from randomized controlled phase 2 and 3a trials
43. Effect of CPAP on arterial stiffness in severely obese patients with obstructive sleep apnoea
44. Effects of canagliflozin on body weight and relationship to HbA1c and blood pressure changes in patients with type 2 diabetes
45. THERAPEUTICS: Glucagon-like peptide-1 analogues for type 2 diabetes
46. Long‐term effects of dapagliflozin plus saxagliptin versus glimepiride on a background of metformin in patients with type 2 diabetes: results of a 104‐week extension to a 52‐week randomised, phase 3 study and liver fat MRI sub‐study
47. Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus in the DECLARE–TIMI 58 trial
48. Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus in the DECLARE–TIMI 58 trial.
49. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension.
50. The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.